Petlife Pharmaceuticals Stock Net Income
| PTLF Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Petlife Pharmaceuticals, as well as the relationship between them.
Petlife Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Petlife Pharmaceuticals' valuation are provided below:Petlife Pharmaceuticals does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Petlife |
Petlife Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Petlife Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Petlife Pharmaceuticals.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Petlife Pharmaceuticals on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Petlife Pharmaceuticals or generate 0.0% return on investment in Petlife Pharmaceuticals over 90 days. Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pe... More
Petlife Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Petlife Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Petlife Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Petlife Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Petlife Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Petlife Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Petlife Pharmaceuticals historical prices to predict the future Petlife Pharmaceuticals' volatility.Petlife Pharmaceuticals Backtested Returns
We have found three technical indicators for Petlife Pharmaceuticals, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Petlife Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Petlife Pharmaceuticals has perfect predictability. Overlapping area represents the amount of predictability between Petlife Pharmaceuticals time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Petlife Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current Petlife Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Petlife Pharmaceuticals reported net income of (23.26 Million). This is 106.81% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 104.07% higher than that of the company.
Petlife Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petlife Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Petlife Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petlife Pharmaceuticals by comparing valuation metrics of similar companies.Petlife Pharmaceuticals is currently under evaluation in net income category among its peers.
Petlife Fundamentals
| Return On Asset | -13.62 | |||
| Current Valuation | 1.19 M | |||
| Shares Outstanding | 196.75 M | |||
| Shares Owned By Insiders | 6.42 % | |||
| Price To Earning | 0.01 X | |||
| Gross Profit | (17.91 K) | |||
| EBITDA | (22.87 M) | |||
| Net Income | (23.26 M) | |||
| Cash And Equivalents | 7.86 K | |||
| Total Debt | 801.65 K | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (318.92 K) | |||
| Earnings Per Share | 0.11 X | |||
| Beta | 0.98 | |||
| Market Capitalization | 393.5 K | |||
| Total Asset | 55 K | |||
| Retained Earnings | (3.81 M) | |||
| Working Capital | (649 K) | |||
| Current Asset | 5 K | |||
| Current Liabilities | 654 K | |||
| Net Asset | 55 K |
About Petlife Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petlife Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petlife Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petlife Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Petlife Pink Sheet
Petlife Pharmaceuticals financial ratios help investors to determine whether Petlife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Petlife with respect to the benefits of owning Petlife Pharmaceuticals security.